APOL1 and COVID-19: Innate immune responses to viruses can drive APOL1 kidney disease in patients with APOL1 high-risk genotypes as was demonstrated in case series of collapsing glomerulopathy caused by therapeutic administration of interferon products and in patients infected with COVID-19 (29, 30).